SUBSCRIBE
SUBSCRIBE
News   Business

DNAPrint Genomics Inc. Selects PT-502 Lead Research Compound For Development Of Drug For Treating Depression

July 17, 2006 | 
1 min read
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced it has confirmed positive results in an animal model for anti-depressant activity for its PT-502 lead compound being developed with the Massachusetts College of Pharmacy and Health Sciences.
Alliances
MORE ON THIS TOPIC
Collage image of people arms gloves hold equipment hit hammer cut saw nail gun isolated on creative white background.
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
February 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
 · 
4 min read
 · 
Annalee Armstrong
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
BMS, Catalent Further Whittle Workforces
February 23, 2026
 · 
57 min read
 · 
BioSpace Editorial Staff
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker